FindTrial
Sign In

Accurate diagnosis and integrative treatment for Behcet's Disease

Accurate diagnosis and integrative treatment for Behcet's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16009621
Enrollment
Unknown
Registered
2016-10-26
Start date
2017-01-01
Completion date
Unknown
Last updated
2018-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet’s Disease

Interventions

intergrative medication group:EULAR+Chinese medicine
EULAR group:EULAR treatment guidline

Sponsors

Huadong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patiens with Behcet's Disease.

Exclusion criteria

Exclusion criteria: 1. infection, cancer and other autoimmune disease; 2. serve heart disease, liver dysfunction, kidney failure.

Design outcomes

Primary

MeasureTime frame
healtine time;remission period;—

Secondary

MeasureTime frame
erythrocyte sedimentation rate;C-reactive protein;incidence of side effects;—

Countries

China

Contacts

Public ContactGuan Jianlong

Huadong Hospital

guanjianlong@medmail.com.cn+86 18121227537

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026